PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01Regulation FD Disclosure

On January 3, 2023, Protalix BioTherapeutics, Inc. (the "Company") issued a press release containing a copy of a letter to its stockholders discussing recent regulatory and clinical developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K ("Current Report").

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits

Exhibit No.   Description
99.1            Press Release dated January 3, 2023
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses